Entrada Therapeutics rises on UK approval for muscle-wasting drug study

Drug developer Entrada Therapeutics' TRDA.O shares rise 2.5% to $10.75

Company says it has received authorization from UK's regulatory agency to begin an early-stage study for an experimental drug, ENTR-601-45, for potential treatment of Duchenne muscular dystrophy, a type of muscle-wasting disorder

Entrada says it is on track to start study in Q3 2025

Company's shares have fallen 22.5% in past 12 months